ArticleCancer gene therapy2001
Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector.
Article in Cancer gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma.Journal of experimental & clinical cancer research : CR · 2010Trial
- AAV for ovarian cancer gene therapy.Cancer gene therapy · 2025Review
- Protection is not always a good thing: The immune system's impact on gene therapy.Genetics and molecular biology · 2022Article
- A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade.Journal of translational medicine · 2019Article
- The Journey ofFrontiers in immunology · 2018Review
- Low risk HPV-6E6 induces apoptosis in bone marrow-derived dendritic cells.Oncology letters · 2018Article
- Article
- Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity.Experimental and therapeutic medicine · 2012Article
- AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC.Oncoimmunology · 2012Article
- Comparison of AAV/IL-7 autocrine (T cell) versus paracrine (DC) gene delivery for enhancing CTL stimulation and function.Cancer immunology, immunotherapy : CII · 2010Article
- Autocrine, not paracrine, interferon-gamma gene delivery enhances ex vivo antigen-specific cytotoxic T lymphocyte stimulation and killing.Journal of biomedicine & biotechnology · 2010Article
- Therapeutic vaccines against human papillomavirus and cervical cancer.The open virology journal · 2009Article
- Effects of herpes simplex virus amplicon transduction on murine dendritic cells.Human gene therapy · 2009Article
- Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation.Journal of translational medicine · 2009Article
- Transduction of PACAP38 protects primary cortical neurons from neurotoxic injury.Neuroscience letters · 2008Article
- Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells.Journal of translational medicine · 2008Article
- Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2.Journal of virology · 2007Article
- Adeno-associated virus vectors: potential applications for cancer gene therapy.Cancer gene therapy · 2005Review
- T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.British journal of cancer · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have shown that the pulsing of dendritic cells (DCs) with human papillomavirus type 16 (HPV-16) antigen proteins by lipofection stimulates class I-restricted cytotoxic T lymphocyte (CTL) response against primary cervical cancer cells. Also, we have shown that adeno-associated virus (AAV) was able to effectively deliver a cytokine gene into DCs. It has been our hypothesis that the delivery of antigen genes into DCs, resulting in endogenous and continuous antigen protein expression, may result in an improvement in T-cell priming by DCs. Here, DCs are pulsed (infected) with an AAV vector containing the HPV-16 E6 gene. After infection, transduced E6 gene mRNA expression and vector chromosomal integration could be identified in infected DCs. Furthermore, priming rosettes formed at early times when the AAV/E6 vector was used. Most importantly, AAV/E6 vector pulsing of DCs induced, after only 7 days of priming, a strong CTL response against primary cervical cancer cell lines, compared to bacterial E6 protein lipofection. Killing was significantly blocked by the addition of anti-MHC class I antibodies. Fluorescence-activated cell sorter (FACS) analysis of resulting primed cell populations revealed higher levels of CD8+ T cells by AAV-based pulsing, with little evidence of CD56 (NK). FACS analysis of the DC populations revealed that AAV/E6 vector-pulsed DCs had higher levels of CD80 and lower levels of CD86 than protein-pulsed DCs. These data suggest that rAAV may be appropriate for antigen pulsing of DCs for immunotherapy protocols. Finally, our protocol represents an advance in regards to the time needed for generating a CTL response compared to other techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.